Ironwood Pharmaceuticals IRWD Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $220.47M+103% | $215.46M+143% | $140.41M+59.2% | $92.85M-12.0% | $108.48M-10.7% | ||
| $105.84M+166% | $46.75M-42.9% | $120.37M+58.0% | $86.17M+48.3% | $39.77M-44.8% | ||
| $5.98M-51.5% | $11.98M+0.5% | $13.07M-7.9% | $12.73M-12.5% | $12.33M-15.7% | ||
| $332.29M+107% | $274.18M+50.3% | $273.84M+53.3% | $191.75M+7.6% | $160.58M-22.9% | ||
| $3.17M-25.6% | $3.41M-24.2% | $3.67M-23.5% | $3.93M-22.5% | $4.26M-19.5% | ||
| $8.9M-16.2% | $9.34M-15.3% | $9.78M-14.5% | $10.2M-13.7% | $10.62M-13.0% | ||
| $1.84M-30.9% | $2.04M-28.7% | $2.25M-26.7% | $2.45M-25.1% | $2.66M-23.6% | ||
| $4.14M-25.3% | $4.5M-24.0% | $4.84M-22.9% | $5.15M+21.0% | $5.54M+63.0% | ||
| $434.57M+32.8% | $396.9M+13.1% | $396.06M+1.7% | $342.95M-13.3% | $327.21M-25.4% | ||
| $3.24M-44.4% | $2.9M+36.2% | $1.61M-50.2% | $1.39M-57.0% | $5.83M-6.3% | ||
| $3.27M+2.0% | $3.25M+2.0% | $3.24M+2.0% | $3.22M+2.0% | $3.2M+2.0% | ||
| $199.86M— | $199.68M— | $199.51M— | $199.33M— | —— | ||
| $236.31M+391% | $242.22M+524% | $242.5M+391% | $232.53M+411% | $48.1M-80.9% | ||
| $9.23M-21.2% | $9.87M-19.8% | $10.5M-18.5% | $11.12M-17.4% | $11.72M-16.3% | ||
| $12.5M-16.2% | $13.12M-15.3% | $13.73M-14.5% | $14.34M-13.7% | $14.92M-13.0% | ||
| $21.17M+22.4% | $21.65M+26.6% | $22.22M-44.1% | $22.47M-35.3% | $17.29M-41.2% | ||
| $165K+1.9% | $163K+1.9% | $163K+1.9% | $162K+1.3% | $162K+1.9% | ||
| $1.42B+1.1% | $1.41B+1.3% | $1.41B+1.3% | $1.41B+1.7% | $1.4B+2.0% | ||
| -$1.63B+5.9% | -$1.67B+1.4% | -$1.67B+1.7% | -$1.71B-0.5% | -$1.74B-1.9% | ||
| -$795K-370% | -$1.06M-215% | -$1.71M+16.5% | -$2.03M-331% | $294K+132% | ||
| -$217.14M+35.0% | -$261.84M+13.1% | -$264.16M+15.2% | -$308.16M+4.2% | -$334.05M-1.1% | ||
| $434.57M+32.8% | $396.9M+13.1% | $396.06M+1.7% | $342.95M-13.3% | $327.21M-25.4% | ||
| $4.14M-25.3% | $4.5M-24.0% | $4.84M-22.9% | $5.15M+21.0% | $5.54M+63.0% | ||
| $8.9M-16.2% | $9.34M-15.3% | $9.78M-14.5% | $10.2M-13.7% | $10.62M-13.0% | ||
| $84.24M-41.3% | $103.43M-28.3% | $101.69M-45.1% | $129.46M-32.9% | $143.56M-30.4% | ||
| $1.84M-30.9% | $2.04M-28.7% | $2.25M-26.7% | $2.45M-25.1% | $2.66M-23.6% | ||
| $8.9M-16.2% | $9.34M-15.3% | $9.78M-14.5% | $10.2M-13.7% | $10.62M-13.0% | ||
| $4.14M-25.3% | $4.5M-24.0% | $4.84M-22.9% | $5.15M+21.0% | $5.54M+63.0% | ||
| $8.9M-16.2% | $9.34M-15.3% | $9.78M-14.5% | $10.2M-13.7% | $10.62M-13.0% | ||
| $4.14M-25.3% | $4.5M-24.0% | $4.84M-22.9% | $5.15M+21.0% | $5.54M+63.0% | ||
| $27.9M-16.6% | $33.24M+23.8% | $34.62M+3.1% | $24.03M-25.8% | $33.44M+6.5% | ||
| $2.04M-63.7% | $3.15M-52.9% | $3.53M-62.5% | $4.55M-32.3% | $5.63M-52.6% | ||
| $199.86M— | $199.68M— | $199.51M— | $199.33M— | —— | ||
| $385M0.0% | $385M0.0% | $385M-3.8% | $385M-9.4% | $385M+40.0% | ||
| $212.36M+1,323% | $212.8M+1,274% | $213.24M+1,228% | $213.67M+1,186% | $14.92M-93.1% | ||
| $1.42B+1.1% | $1.41B+1.3% | $1.41B+1.3% | $1.41B+1.7% | $1.4B+2.0% | ||
| $165K+1.9% | $163K+1.9% | $163K+1.9% | $162K+1.3% | $162K+1.9% | ||
| $385M0.0% | $385M0.0% | $385M-3.8% | $385M-9.4% | $385M+40.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ironwood Pharmaceuticals's total assets?
- Ironwood Pharmaceuticals (IRWD) holds $434.6M in total assets, up 32.8% year over year.
- How much debt does Ironwood Pharmaceuticals have?
- Ironwood Pharmaceuticals carries $212.4M in total debt against -$217.1M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does Ironwood Pharmaceuticals have?
- Ironwood Pharmaceuticals holds $220.5M in cash and equivalents.
- Can Ironwood Pharmaceuticals cover its short-term obligations?
- Its current ratio is 1.41 — current assets exceed current liabilities.
- Where does Ironwood Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Ironwood Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
